Mebendazole clinical pharmacology

Following administration of 100 mg twice daily for three consecutive days, plasma levels of mebendazole and its primary metabolite, the 2-amine, do not exceed 0.03 mcg/mL and 0.09 mcg/mL, respectively. All metabolites are devoid of anthelmintic activity. In man, approximately 2% of administered mebendazole is excreted in urine and the remainder in the feces as unchanged drug or a primary metabolite.

Mebendazole inhibits the formation of the worms’ microtubules and causes the worms’ glucose depletion.^[1]

Adapted from the FDA Package Insert.